Leading New York Ophthalmologist Integrates Tixel® into Dry Eye Treatments - Welcomes Rapid Growth

News provided by

Jun 03, 2025, 13:25 ET

WATERTOWN, N.Y., June 3, 2025 /PRNewswire/ -- Dr. Noaman Sanni, a leading ophthalmologist and CEO of Center for Sight New York, has witnessed significant patient and revenue growth after adding Tixel i into his practice. Tixel i, Novoxel's FDA-cleared device, utilizes patented Thermo-Mechanical Action^® (TMA) to effectively treat Meibomian Gland Dysfunction (MGD) – a common cause of dry eye – in under two minutes.

Dr. Sanni of Center for Sight New York treating a patient for dry eye using Tixel i®.

"We were not really focused on the business aspect, because we were focusing on the medical aspect and helping our patients. Therefore, I was surprised at the positive financial impact due to rapid patient acceptance.” - Dr. Sanni

Within just two months, Dr. Sanni's team treated over 225 patients, making Tixel i a truly transformative addition to their dry eye protocols. Dr. Sanni noted, "We were not really focused on the business aspect, because we were focusing on the medical aspect and helping our patients. Therefore, I was surprised at the positive financial impact due to rapid patient acceptance."

CLINICALLY PROVEN RESULTS - Tixel i isn't just praised by patients; it's backed by strong clinical data. A pivotal trial showed remarkable improvements:

Tear Break-Up Time (TBUT) improved from severe to normal physiological range and sustained for 6 months.
Meibomian Gland Score (MGS) increased by over 17 points, comparable to or exceeding thermal pulsation systems.
Ocular Surface Disease Index (OSDI) scores dropped by more than 21 points, indicating a significant improvement in patients' quality of life.
Crucially, no adverse device-related effects were reported.

PHYSICIAN ENDORSEMENT - Dr. Debra Koloms, Medical Director at Center for Sight New York, personally experienced Tixel i treatment for her own dry eye. "After 2 Tixel i treatments, I no longer need punctal plugs or drops," she shared. After personally treating over 50 patients in six weeks, Dr. Koloms declared, "In 40 years of practice, this is the most impressive treatment I've ever seen for Meibomian Gland Dysfunction."

Center for Sight New York offers consultations and Tixel i treatment previews for those interested in learning more about this innovative dry eye solution.

Novoxel, Tixel, Thermo-Mechanical Action, and TMA are registered trademarks of Novoxel LTD.

ABOUT NOVOXEL
Established in 2011, Novoxel Ltd. focuses on scientific and clinical innovation, holding numerous patents worldwide. Their Tixel family of products utilize proprietary Thermo-Mechanical Action (TMA^®) to deliver noticeable clinical results. These treatments are non-invasive, radiation-free, require minimal downtime, and involve no expensive single-use cartridges, bleeding, or significant pain. To learn more, visit tixel.us/contactus.

ABOUT CENTER FOR SIGHT
Established in the 1940s, Center for Sight New York is one of Northern New York's largest and most respected eye care practices, with locations in Watertown and Ogdensburg. Under the leadership of Dr. Noaman Sanni since 1995, the practice boasts a team of board-certified ophthalmologists and skilled technicians. They provide state-of-the-art diagnostics and advanced treatments with a patient-centered approach, aiming to improve quality of life through exceptional vision solutions.

SOURCE Novoxel Inc.